Viridian Therapeutics, Inc.\DE (VRDN) Profit After Tax (2016 - 2025)
Historic Profit After Tax for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to -$34.6 million.
- Viridian Therapeutics, Inc.\DE's Profit After Tax rose 5488.4% to -$34.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.0 million, marking a year-over-year decrease of 1746.01%. This contributed to the annual value of -$269.9 million for FY2024, which is 1355.09% down from last year.
- Latest data reveals that Viridian Therapeutics, Inc.\DE reported Profit After Tax of -$34.6 million as of Q3 2025, which was up 5488.4% from -$100.7 million recorded in Q2 2025.
- Over the past 5 years, Viridian Therapeutics, Inc.\DE's Profit After Tax peaked at -$14.0 million during Q3 2021, and registered a low of -$100.7 million during Q2 2025.
- Its 5-year average for Profit After Tax is -$49.4 million, with a median of -$47.7 million in 2023.
- The largest annual percentage gain for Viridian Therapeutics, Inc.\DE's Profit After Tax in the last 5 years was 6810.08% (2021), contrasted with its biggest fall of 17916.08% (2021).
- Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Profit After Tax stood at -$28.9 million in 2021, then crashed by 58.17% to -$45.8 million in 2022, then tumbled by 46.03% to -$66.9 million in 2023, then fell by 19.24% to -$79.7 million in 2024, then soared by 56.6% to -$34.6 million in 2025.
- Its Profit After Tax stands at -$34.6 million for Q3 2025, versus -$100.7 million for Q2 2025 and -$86.9 million for Q1 2025.